Alzamend Neuro, Inc. (ALZN)
Contact Details
| Address:3802 Spectrum Blvd, Tampa, Florida 33612 United States |
|
| Phone | 844-722-6333 |
| Website | alzamend.com |
Stock Information
| Ticker Symbol | ALZN |
| Exchange | NASDAQ |
| Fiscal Year | May - April |
| Reporting Currency | US Dollars |
| IPO Price | $5.00 |
| CIK Code | 1677077 |
| Employer ID | 81-1822909 |
Company Description
Alzamend Neuro is a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders.
With our two current and future product candidates, we aim to bring treatments or cures to market at a reasonable cost as quickly as possible. Our primary target is Alzheimer’s disease.
Existing Alzheimer’s treatments only temporarily relieve symptoms but do not slow or halt the underlying worsening of the disease, which currently affects roughly 6.2 million Americans and that number is expected to grow to 13 million individuals by 2050.
Our lead product candidate that we have licensed and will first move to clinical development in humans is an ionic cocrystal of lithium for the treatment of Alzheimer’s and other neurodegenerative diseases and psychiatric disorders.
We submitted a Pre-Investigational New Drug (“PIND”) briefing package to the FDA in July 2019 and have begun the process of finalizing the Investigational New Drug (“IND”) application.
We currently expect to submit by June 30, 2021 the IND for FDA approval to begin a Phase I clinical trial with human subjects. We have an additional preclinical candidate for Alzheimer’s indication, AL002, which has transitioned from early-stage development to an extensive program of preclinical study and evaluation, with an anticipated completion date of May 31, 2021.
Key Executives
| Name | Position |
|---|---|
| Stephan Jackman | Chief Executive Officer and Director |
| Kenneth S. Cragun CPA | Chief Financial Officer and Treasurer |
| Henry C.W. Nisser Esq. | Executive Vice President, General Counsel and Director |
| Milton Charles Ault III | Founder and Executive Chairman |
| Lien T. Escalona | Chief Financial Officer |
| David J. Katzoff | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 23, 2021 | 8-K | Current report |
| Jul 22, 2021 | 4 | Statement of changes in beneficial ownership of securities |
| Jul 19, 2021 | 4 | Statement of changes in beneficial ownership of securities |
| Jul 16, 2021 | 4 | Statement of changes in beneficial ownership of securities |
| Jul 16, 2021 | 4 | Statement of changes in beneficial ownership of securities |
| Jul 16, 2021 | 4 | Statement of changes in beneficial ownership of securities |
| Jul 16, 2021 | 4 | Statement of changes in beneficial ownership of securities |
| Jul 15, 2021 | 4/A | Statement of changes in beneficial ownership of securities |
| Jul 14, 2021 | 4 | Statement of changes in beneficial ownership of securities |
| Jul 13, 2021 | S-8 | Securities to be offered to employees in employee benefit plans |
| View All SEC filings | ||